Treat Cancer at Any Stage

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response to Treat Cancer at Any Stage

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

Tumor
Injection

DfuseRx℠ is our novel proprietary penetration enhancer platform technology that enables therapeutic agents to be injected directly into solid tumors for improved absorption.

Diffusion
Through Tumor

Once injected, DfuseRx enables the injected drug solution to disperse throughout the tumor and increases the drug’s diffusion into cancer cells.

Localized
Cell Death

The absorbed active agents in the injected tumor induce cancer cell death, without disruption of the cell membrane, in a manner that results in an influx of immune cells throughout the tumor.

System-wide
Immune Response

Tumor cell death exposes the immune system to antigens of the patient’s own cancer, inducing a personalized CD4+ and CD8+ T cell response, attacking the site of the former tumor while attacking distal cancer sites.

Increased
Survival

Exploratory analysis of data from a Phase 1/2 trial of relapsed and refractory solid tumor patients with a variety of cancers indicates an association between percent of tumor burden treated and survival.

Technology and Clinical Data

DfuseRxSM is our novel proprietary product discovery technology that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption. The technology makes use of novel dispersion and cell penetration enhancer molecules that we have identified.
Play Video

Register for News Updates:

Subscribe to our company news email list and receive news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.

Latest Tweets:

#ASCO22
Effect of INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a phase 1/2 study of solid tumors w & w/o pembro [Intensity IT-01; Merck -KNA10]
Presenter: Jacob Thomas, MD
Immunotherapy
Discussion Session 06/05/2022, 12:30PM EDT
Hall D2

#ASCO22
INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas
Presenter: Matthew Ingham, MD
Poster Discussion Session/Sarcoma
Date/Time: Sunday, 06/0522, 12:30 – 2:00 PM EDT
Room S404
Abstract#:11515
Poster:420

Today @IntensityInc announced that New Clinical Data in Solid Tumors for our Lead Asset, INT230-6, were Accepted for Two Poster Discussion Sessions and Three Poster Presentations at the Upcoming 2022 American Society of Clinical Oncology (#ASCO22) Annual Meeting.

#POTUS spoke tonight about cutting deaths from #CANCER, new technologies such as those of @IntensityInc are able to do so.

This morning we announced breast #cancer data from the dose escalation phase 1 portion of our study IT-01 at the San Antonio Breast Cancer Symposium #SABCS21. Please go http://www.intensitytherapeutics.com to see the news and data.

Load More...